FDA approves first herbal medicine for clinical trial on Coronavirus treatment
The Ghana Food and Drugs Authority (FDA) together with the National Medicine Regulatory Agency (NMRA) has approved a herbal medicine called Cryptolepis Sanguinolenta locally known as ‘Nibima’ for clinical trials for the treatment of coronavirus (Covid-19).
In a statement cited by Spot On News, the Chief Executive Officer (CEO) of FDA indicated that the approval of the herbal medicine comes on the back of laboratory studies conducted by the Kwame Nkrumah University of Science and Technology (KNUST) research team which proves the efficacy of the medicine against the novel coronavirus.
READ ON: Mahama is just not ready for the election petition trial— Frank Davies
Delese Mimi Darko said after a detailed assessment of the application gave the requisite regulatory authorisation for the conduct of the trial.
“In the search for the treatment for the ongoing Covid-19 pandemic, researchers from the School of Public Health at the KNUST submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis Sanguinolenta as a potential treatment for covid-19.”
“This follows results from the laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits,” she noted.
READ ALSO: I nearly died from COVID-19— Celestine Donkor shares experience
Under part 8 (section 150-166) of the Public Health Act 2012(Act 851), gives the authority the legal mandate to regulate clinical trials of drugs, herbal medicinal products, cosmetics or medical devices.
She revealed that the trial would be conducted at two sites.
The Chief Director also assured the general public that it remains committed to protecting the health and safety of consumers.
READ MORE: Liberian rebel in trial for killing more than 250,000 people in Liberia civil war
It further admonished citizens to report any suspicious activities on FDA regulated products to the Authority.
Source: www.spotonnews.net
